NCT06794957View on ClinicalTrials.gov

A Study of AL8326 in Non-Small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

AL8326 tablets

10mg/tablet;Oral administration, once daily.

Trial Locations (10)

210029

Nanjing Chest Hospital, Nanjing

230031

Anhui Provincial Cancer Hospital, Hefei

233004

The First Affiliated Hospital of Bengbu Medicaal University, Bengbu

242099

Xuancheng People´s Hospital, Xuancheng

310016

Sir Run Run Shaw Hospital (SRRSH),affiliated with Zhejiang University School of Medicine, Hangzhou

314001

The First Hospital Of Jiaxing, Jiaxing

430079

Hubei Cancer Hospital, Wuhan

450052

Henan Cancer Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

455100

Anyang Cancer Hospital, Anyang

Sponsors
All Listed Sponsors
lead

Advenchen Laboratories, LLC

INDUSTRY